Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue
Conditions
Interventions
Intervention1: Group A- Trial drug -(comprising 15 sample size) Application Of Trial drug Dashang Shunti Lepa
Group B-(comprising 15 sample size)application of Placebo
: 1.Consent form
2.Data collec
Sponsors
Vd Shweta Santosh Naik
Eligibility
Inclusion criteria
Inclusion criteria: 1.All Patient presenting with sign and symptoms of sandhi shoth and shula will be selected. 2. Patients of agantuja shotha without fracture will be included in Study. 3.Patients of either sex in age group of 20 -60 years will be included in study.3. 4.Uncomplicated cases of Sandhi Shotha and Shula will be selected. 5.Patients willing to participate in the trial will be included in study.
Exclusion criteria
Exclusion criteria: 1.Patients age less than 20yrs and more than 60 yrs will be excluded. 2. Patients having complications of Sandhi Shoth and Shula like tuberculosis, bone metastasis, psoriatic arthritis and bony deformities of joints (viz.varus/valgus) will be excluded. 3.Patients having pleural effusion, severe anemia,accelerated hypertension, renal failure and chronic cardiac failure will be excluded. 4.Those patients not willing to be part of trial and not giving written consent will be excluded. 5.Patients undergoing regular treatment for other severe illnesses will be excluded. 6.Patients on prolonged corticosteroids will be excluded. _______________
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the trial drug Dashang Sunthi lepa will reduce Sandhi(joints) Shoth(swelling) and Shula(pain) It is expected that the trial drug Dashang Sunti lepa will reduce Sandhi Shoth and Shula Timepoint: 14 days It is expected that the trial drug Dashang Sunti lepa will reduce Sandhi Shoth and Shula | — |
Secondary
| Measure | Time frame |
|---|---|
| If trial drug found effective in treating joints swelling and pain can be used widely in treating the sameTimepoint: 14 days;Objective Parameters: Change in ESR and CRP Quantitative in comparison to placebo before and after treatment on 7th and 14th day. Timepoint: 1day 7day 14 day | — |
Countries
India
Contacts
Public ContactDr Basil Cardozo Guide
Gomantak Ayurveda Mahavidyalaya and Research Centre Vazem Shiroda Goa
Outcome results
None listed